SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
The private funding rose 38% amid growing international collaborations and CDMO demand
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Subscribe To Our Newsletter & Stay Updated
